Aug 23, 2016
This study aimed to inform Hepatitis C (HCV) treatment by (1) better understanding the nexus of factors physicians consider when making HCV treatment decisions; (2) investigating the comparative influence and importance of specific factors and the trade-offs implicated in the decisionmaking process; and (3) examining how much thrombocytopenia impacts treatment decisions and how it impacts treatment.
To meet this goal, we conducted five analyses, focusing on four European countries characterised by different approaches to healthcare organisation and financing, which alongside cultural differences may have potential implications for treatment pathways for patients with HCV infection. These were: France, Italy, Spain, and the United Kingdom. These analysis included:
The five analyses build on one another, with the first three providing evidence that fed into the design of the DCEs and with the DCE results in turn serving as the key inputs into building the scenarios for the expert workshop.
Our methodological approach
Literature review identifying the diversity of factors influencing treatment decisions
Key informant interviews identifying and understanding the factors influencing treatment decisions
Mapping patients' journeys for HCV treatment
Using discrete choice experiments to quantify physicians' treatment decisions
Using scenario building to explore future potential situations
Literature review search strategy
Internal key informant interview guide (for interviewer)
Profile of interviewees
Full discrete choice experiment questionnaire